Wall Street analysts forecast that FibroGen Inc (NASDAQ:FGEN) will announce earnings of ($0.35) per share for the current quarter, according to Zacks. Three analysts have issued estimates for FibroGen’s earnings. The highest EPS estimate is ($0.30) and the lowest is ($0.44). FibroGen reported earnings of ($0.50) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 30%. The firm is scheduled to report its next quarterly earnings results on Wednesday, November 14th.
On average, analysts expect that FibroGen will report full year earnings of ($1.05) per share for the current year, with EPS estimates ranging from ($1.87) to ($0.47). For the next financial year, analysts expect that the business will post earnings of ($1.38) per share, with EPS estimates ranging from ($3.11) to ($0.16). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that follow FibroGen.
FibroGen (NASDAQ:FGEN) last posted its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.31. FibroGen had a negative net margin of 85.59% and a negative return on equity of 22.60%. The business had revenue of $43.95 million for the quarter, compared to analysts’ expectations of $28.70 million.
Shares of NASDAQ FGEN traded up $1.18 during trading on Friday, reaching $55.81. 1,720 shares of the stock were exchanged, compared to its average volume of 524,300. The company has a current ratio of 7.95, a quick ratio of 7.95 and a debt-to-equity ratio of 0.19. The stock has a market cap of $4.70 billion, a P/E ratio of -31.75 and a beta of 1.81. FibroGen has a twelve month low of $40.74 and a twelve month high of $68.55.
In other FibroGen news, Director Jorma Routti sold 6,000 shares of the business’s stock in a transaction on Thursday, August 9th. The shares were sold at an average price of $59.93, for a total transaction of $359,580.00. Following the completion of the sale, the director now owns 137,540 shares in the company, valued at $8,242,772.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Toshinari Tamura sold 12,000 shares of the business’s stock in a transaction on Wednesday, August 22nd. The shares were sold at an average price of $60.65, for a total transaction of $727,800.00. Following the sale, the director now owns 63,700 shares of the company’s stock, valued at approximately $3,863,405. The disclosure for this sale can be found here. In the last 90 days, insiders sold 213,773 shares of company stock valued at $12,753,794. Insiders own 8.96% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the business. Wealth Alliance Advisory Group LLC bought a new stake in FibroGen during the second quarter valued at $204,000. Oppenheimer Asset Management Inc. bought a new stake in FibroGen during the second quarter valued at $236,000. Dynamic Technology Lab Private Ltd bought a new stake in FibroGen during the first quarter valued at $258,000. Fred Alger Management Inc. bought a new stake in FibroGen during the second quarter valued at $313,000. Finally, Nisa Investment Advisors LLC increased its stake in FibroGen by 1,829.4% during the third quarter. Nisa Investment Advisors LLC now owns 6,174 shares of the biopharmaceutical company’s stock valued at $375,000 after purchasing an additional 5,854 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.
FibroGen Company Profile
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Featured Article: How to Invest in Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.